Rifampin Capsules — Class II drug recall D-0011-2023
Terminated recall by Golden State Medical Supply Inc., reported 2022-10-26, distributed nationwide. Failed impurities/degradation specifications: Finished product exceeds the 5 ppm interim limit for 1-Methyl-4-
| Recall number | D-0011-2023 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Golden State Medical Supply Inc., Camarillo, CA, United States |
| Recall initiated | 2022-10-06 |
| Classified | 2022-10-17 |
| Reported by FDA | 2022-10-26 |
| Terminated | 2025-03-19 |
| Distributed | Nationwide (US) |
| Reason classes | specification failure |
| NDC | 51407-0323-01, 51407-0323-30, 51407-0323-60 |
| Expiration dates | 2023-01-31, 2023-03-31 |
Product
Rifampin Capsules, USP, 300 mg, packaged in a) 30-count bottle (NDC 51407-323-30), b) 60-count bottle (NDC 51407-323-60), c) 100-count bottle (NDC 51407-323-01), Rx only, Manufactured by Patheon Pharmaceuticals Inc., OH, Packaged by GSMS, Incorporated, CA.
Reason for recall
Failed impurities/degradation specifications: Finished product exceeds the 5 ppm interim limit for 1-Methyl-4-Nitrosopoperazine (MNP).
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0011-2023. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.